Fierce Biotech3d
Agomab's ALK5 inhibitor hits target in phase 2 Crohn's disease trial
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...
Le Lézard1d
MyHealthTeam Launches 'MyCrohnsAndColitisTeam en español,' a Spanish-Language Patient Community for People With Crohn's Disease or Ulcerative Colitis
MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has ...
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...